For PTLA investors, liquidity is clearly not the main concern. Rather, the main concern should be the shortcomings of the phase-3 Betrixaban program (#msg-89332563, #msg-89290904).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”